Kiniksa Pharmaceuticals International, plc KNSA Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's change in accrued liabilities?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported change in accrued liabilities of -$5.05M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's change in accrued liabilities changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's change in accrued liabilities decreased by 40.4% year-over-year, from -$3.6M to -$5.05M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's change in accrued liabilities?
- Over 3 years (2022 to 2025), Kiniksa Pharmaceuticals International, plc's change in accrued liabilities has grown at a 116.2% compound annual growth rate (CAGR), from -$3.71M to $37.5M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.